---
title: "InflaRx N.V. (IFRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IFRX.US.md"
symbol: "IFRX.US"
name: "InflaRx N.V."
industry: "Biotechnology"
datetime: "2026-05-20T06:52:08.649Z"
locales:
  - [en](https://longbridge.com/en/quote/IFRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IFRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IFRX.US.md)
---

# InflaRx N.V. (IFRX.US)

## Company Overview

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.inflarx.de](https://www.inflarx.de) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 246 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -75.48% |  |
| Net Profit YoY | -4.09% |  |
| P/B Ratio | 8.26 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 349084075.83 |  |
| Revenue | 34261.37 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -79.94% | E |
| Profit Margin | -146303.92% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | -75.48% | E |
| Net Profit YoY | -4.09% | C |
| Total Assets YoY | -40.51% | E |
| Net Assets YoY | -44.58% | E |
| Cash Flow Margin | 66.86% | C |
| OCF YoY | -75.48% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 24.54% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - InflaRx N.V.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-75.48%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.09%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "8.26",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "349084075.83",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "34261.37",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-79.94%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-146303.92%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-75.48%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.09%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-40.51%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-44.58%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "66.86%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-75.48%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.54%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.96 | 410/386 | - | - | - |
| PB | 8.26 | 381/386 | 1.53 | 1.29 | 0.83 |
| PS (TTM) | 10188.85 | 304/386 | 1196.71 | 849.28 | 420.82 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 86% |
| Hold | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.37 |
| Highest Target | 24.05 |
| Lowest Target | 2.03 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IFRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IFRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IFRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IFRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**